Climb Bio Inc (CLYM)
Healthcare
Biotechnology
11.90 $
-1.5%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Climb Bio Inc (CLYM)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 72.3% of the shares are freely tradable; institutional investors hold 66.5%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
66.5%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.4%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
72.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
16.9%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
57Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RA Capital Management, LLC | 19.74 | 11,300,939 | +0.1 | 03/31/2026 |
| MPM Oncology Impact Management LP | 4.53 | 2,593,439 | -2.9 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 3.35 | 1,916,968 | -0.3 | 03/31/2026 |
| BRAIDWELL LP | 2.67 | 1,529,675 | +0.0 | 03/31/2026 |
| Great Point Partners LLC | 2.33 | 1,334,130 | +36.2 | 03/31/2026 |
| Millennium Management LLC | 2.23 | 1,276,260 | +330.7 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.06 | 1,178,659 | +0.0 | 03/31/2026 |
| Kynam Capital Management, LP | 1.75 | 1,003,341 | -2.4 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| T. Rowe Price Health Sciences | 2.86 | 1,635,973 | +31.1 | 06/30/2026 |
| Vanguard Morn Total Stk Mkt Idx Investor | 2.39 | 1,366,686 | +38.6 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.